Peer-influenced content. Sources you trust. No registration required. This is HCN.

Hepatoma Research is an international peer-reviewed, open access, online journal.

Aims and Scope
The journal focuses on all topics related to hepatoma, including its occurrence, development, diagnosis, and treatment. The coverage also extends to other basic and clinical studies related to statistics, epidemiology, public health, surgery, internal medicine, cell biology, pathology, pathophysiology, immunology, genetics, pharmacology, etc.

  • Carcinogenic mechanism of hepatoma, especially the role of HBV evolution on the development of hepatocellular carcinoma
  • Development of diagnostic, prognostic, and predictive biomarkers for hepatocellular carcinoma and biliary tract cancer
  • Therapeutic options of hepatoma as well as complications of hepatoma including basic and clinical research on animal models, liver transplantation, molecular targeted therapy, immunotherapy, interventional therapy, hepatoma treatment-related drugs, as well as clinical transition of the latest laboratory therapy
  • Epidemiology of liver cancer and biliary tract cancer: including risk factors of liver cancer and biliary tract cancer, statistics, survival and prognosis, predictive risk models, active prophylaxis of liver cancer and biliary tract cancer. Cohort study and randomized controlled clinical trial are particularly welcome

The journal publishes the following types of articles: Original Article, Review, Systematic Review, Meta-analysis, Case Report, Commentary, Editorial, Research Highlight, etc.

The journal is owned by OAE Publishing Inc.

Publishing Model
Gold open access. All articles published by Hepatoma Research are made freely and permanently accessible online immediately from the date of publication. For further information, please refer to Open Access.


The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form